Dr. Klinghoffer is committed to innovation in early cancer drug development and has dedicated a 25-year career to addressing the challenges of translating laboratory discovery into patient benefit.

Dr. Klinghoffer’s team established the CIVO® platform, which, combined with spatial biology technologies such as Nanostring’s GeoMx DSP and CosMx DMP, enables detailed evaluation of multiple drugs and combinations simultaneously in intact patient tumors. Under his leadership, Presage derives deep mechanistic understanding of drug response via a novel approach to Phase 0 multiplexed microdosing trials. Before joining Presage, Dr. Klinghoffer worked in both small biotech and large pharma settings and at Merck’s Rosetta Inpharmatics, he led a team of scientists focused on identifying and validating cancer targets and predictive biomarkers for novel chemotherapeutics.

Dr. Klinghoffer is an author on over 30 peer-reviewed research publications and is a coinventor on multiple patents related to cancer drug development technologies. He earned his Ph.D. from the University of Colorado Health Sciences Center and was a Special Fellow of the Leukemia and Lymphoma Society as a Postdoctoral Fellow at the Fred Hutchinson Cancer Research Center.